Ascentage Pharma (AAPG) highlights pivotal lisaftoclax ASH 2025 study results in Form 6-K

Rhea-AI Filing Summary

Ascentage Pharma Group International furnished a Form 6-K highlighting two scientific updates for its Bcl-2 inhibitor lisaftoclax. The company reported that pivotal China registrational study data for lisaftoclax were presented in an oral report at the 2025 American Society of Hematology (ASH) Annual Meeting.

Ascentage also noted encouraging data from a Phase Ib/II study of lisaftoclax in venetoclax‑exposed patients with myeloid malignancies, which were shared at ASH 2025. Full details of these results are contained in press releases attached as Exhibits 99.1 and 99.2.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On December 6, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting”. A copy of the press release is furnished as Exhibit 99.1 to this Report. On December 8, 2025, Ascentage Pharma Group International issued a press release entitled “ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances”. A copy fo the press release is furnished as Exhibit 99.2 to this Report.

1

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Press Release dated December 6, 2025
99.2		Press Release dated December 8, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: December 8, 2025	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

FAQ

What does Ascentage Pharma (AAPG) report in its December 2025 Form 6-K?

Ascentage Pharma’s December 2025 Form 6-K reports that it furnished two press releases summarizing new clinical data for its Bcl-2 inhibitor lisaftoclax presented at the 2025 American Society of Hematology (ASH) Annual Meeting, including pivotal China registrational and Phase Ib/II study results.

What pivotal data did Ascentage Pharma (AAPG) present for lisaftoclax at ASH 2025?

Ascentage Pharma reports presenting pivotal China registrational study data for lisaftoclax in an oral report at the 2025 ASH Annual Meeting. The detailed clinical results and their implications are contained in the press release dated December 6, 2025, furnished as Exhibit 99.1 to the Form 6-K.

Which additional lisaftoclax study in venetoclax-exposed patients did AAPG highlight?

The company highlighted encouraging data from a Phase Ib/II study of lisaftoclax in venetoclax‑exposed patients with myeloid malignancies. These findings, presented at ASH 2025, are further described in the press release dated December 8, 2025, furnished as Exhibit 99.2 to the Form 6-K.

How did Ascentage Pharma (AAPG) communicate its ASH 2025 lisaftoclax results to investors?

Ascentage Pharma communicated its ASH 2025 lisaftoclax results via two press releases, dated December 6 and December 8, 2025. These releases, covering pivotal registrational and Phase Ib/II data, were formally furnished to investors as Exhibits 99.1 and 99.2 in a Form 6-K.

Where can investors find detailed clinical information on Ascentage Pharma’s lisaftoclax studies?

Investors can find detailed lisaftoclax clinical information in the press releases attached to the Form 6-K as Exhibits 99.1 and 99.2. These documents summarize pivotal China registrational data and Phase Ib/II results in venetoclax‑exposed myeloid malignancy patients presented at ASH 2025.